According to reports, the incidence of ALK gene rearrangement in NSCLC patients is about 3%–7%,10 whereas the incidence of EGFR mutation is 40%–80%32; the sample size of patients with ALK&ROS1 gene rearrangement is small in our study. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.